Ofatumumab is a feasible alternative anti-CD20 therapy in patients intolerant of rituximab

Br J Haematol. 2019 Feb;184(3):462-465. doi: 10.1111/bjh.15110. Epub 2018 Jan 24.
No abstract available

Keywords: infusion-related reaction; lymphoma; monoclonal antibody; ofatumumab; rituximab.

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / administration & dosage*
  • Antibodies, Monoclonal / adverse effects
  • Antibodies, Monoclonal, Humanized
  • Female
  • Hematologic Neoplasms / drug therapy*
  • Hematologic Neoplasms / pathology
  • Humans
  • Male
  • Middle Aged
  • Rituximab / administration & dosage
  • Rituximab / adverse effects*

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Rituximab
  • ofatumumab